The progress and current status of immunotherapy in acute myeloid leukemia


Recently, there has been remarkable progress in basic and preclinical studies of acute myeloid leukemia (AML). The improved outcomes of AML can largely be attributed to advances in supportive care and hematopoietic cell transplantation as opposed to conventional chemotherapy. However, as the 5-year survival rate remains low due to a high incidence of… (More)
DOI: 10.1007/s00277-017-3148-x


2 Figures and Tables

Slides referencing similar topics